Volume 4 (Issue 1, 2, 3) 2019
Share on whatsapp
Share on twitter
Share on facebook
-
Autism Spectrum Disorder: Medications overview https://doi.org/10.37881/1.4112019, Volume 4, Issue 1 (January-April) [Download Full PDF]
- FDA-approves the first therapy in 2018 for the seizures associated with Dravet syndrome https://doi.org/10.37881/1.412
2019, Volume 4, Issue 1 (January-April) [Download Full PDF]
- Cannabidiol: FDA approved new drug for the Lennox-Gastaut syndrome and Dravet Syndrome: Pharmacotherapeutics review https://doi.org/10.37881/1.413
2019, Volume 4, Issue 1 (January-April) [Download Full PDF]
- Caplacizumab: First FDA-approved therapy in 2019 for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura https://doi.org/10.37881/1.414
2019, Volume 4, Issue 1 (January-April) [Download Full PDF]
- Stiripentol: New approved drug for the Dravet syndrome: Pharmacotherapeutics review https://doi.org/10.37881/1.415
2019, Volume 4, Issue 1 (January-April) [Download Full PDF]
- Siponimod: A new approved oral drug to treat multiple sclerosis https://doi.org/10.37881/1.421
2019, Volume 4, Issue 2 (May-August) [Download Full PDF]
- Istradefylline: A new add-on drug to treat off episodes in adults with Parkinson’s disease https://doi.org/10.37881/1.422
2019, Volume 4, Issue 2 (May-August) [Download Full PDF]
- FDA recalled Ranitidine: What about the consumers who ate Ranitidine with carcinogenic impurity by paying to Pharma companies? https://doi.org/10.37881/1.431
2019, Volume 4, Issue 3 (September-December) [Download Full PDF]
- Top Pharma companies not following current good manufacturing processes: Angiotensin II receptor blockers with carcinogenic impurities: A threat to global public health https://doi.org/10.37881/1.432
2019, Volume 4, Issue 3 (September-December) [Download Full PDF]